The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Standard vs high-dose anthracycline vs anthracycline + gemtuzumab ozogamicin in favorable risk AML
Firas El Chaer, MD, University of Virginia, Charlottesville, VA, shares the results of a real-world analysis comparing the use of standard-dose anthracycline vs high-dose anthracycline vs anthracycline plus gemtuzumab ozogamicin in patients with favorable risk acute myeloid leukemia (AML). Overall, the study found that there were no significant differences between the rates of complete remission (CR), CR with incomplete count recovery (CRi), relapse-free survival (RFS), overall survival (OS), and toxicity profiles. It is still necessary to determine whether measurable residual disease (MRD) negativity rates are higher in patients treated with anthracycline and gemtuzumab ozogamicin. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
